Triore (CEO Woo Sung-ho), a biopharmaceutical development company, announced on the 17th that it recently attracted a Series B round investment of 22.5 billion won.
This Series B round was participated by new investors Woori Venture Partners, Shinhan Venture Investment, Hyundai Technology Investment, Regent Partners, and Snickpick Investment, while existing investors IMM Investment, LSK Investment, KB Investment, Kiwoom Investment, Shinhan Capital, and Jin & Investment Partners also made follow-up investments. This brings Trio’s total investment to approximately KRW 41.5 billion. In particular, this round is being conducted in a multi-closing manner, and follow-up investments from corporate venture capital (CVC) firms that are currently reviewing investment based on collaboration with business divisions are also scheduled, so the total investment scale is expected to increase.
Trior is developing 'TROCAD™', an antibody platform that dramatically improves the therapeutic index of antibody-based treatments, and 'TROSIG™', a novel linker-toxin system that maximizes the drug stability and therapeutic efficacy of antibody-drug conjugates (ADCs). These technologies are evaluated as innovative technologies that can overcome the limitations of existing antibody and ADC treatments. Trior was recently selected for a corporate presentation session at '2025 BIO USA' held in Boston, USA, where it introduced its technology and pipeline, and is actively discussing cooperation and technology transfer with a number of global pharmaceutical companies and domestic and foreign companies.
Since its establishment in 2021, Trioer has steadily accumulated achievements based on its technological prowess and execution capabilities. In 2023, it was selected as a ‘Baby Unicorn’ company by the Ministry of SMEs and Startups, won the ‘Seoul-BMS Innovation Square Challenge’ in the same year, entered the Seoul Bio Hub, and was selected as a ‘D-Unicorn’ company in 2024.
“Triore has the potential to become a game changer that goes beyond the limitations of existing treatments in the antibody and ADC fields,” said Jiwoong Cheon, Managing Director of Woori Venture Partners, which led the new investment. “Based on my experience working at a global pharmaceutical company, I expect that Triore’s technology will lead to a dramatic advancement in the ADC field.”
Trioer CEO Woo Sung-ho said, “This investment is a recognition of our technological innovation and marketability,” and added, “We plan to focus the funds raised on pipeline development and platform technology research, and ultimately, we will focus our capabilities on leading to major achievements such as collaboration with global pharmaceutical companies, technology transfer, and overseas clinical trials.”
You must be logged in to post a comment.